These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 27257183)
1. Statins could be new treatment option in women with oestrogen receptor positive breast cancer. Kmietowicz Z BMJ; 2016 Jun; 353():i3108. PubMed ID: 27257183 [No Abstract] [Full Text] [Related]
2. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. Kumar AS; Campbell M; Benz CC; Esserman LJ J Clin Oncol; 2006 May; 24(13):2127; author reply 2127-8. PubMed ID: 16648516 [No Abstract] [Full Text] [Related]
3. Biomedicine. Defining the "S" in SERMs. Katzenellenbogen BS; Katzenellenbogen JA Science; 2002 Mar; 295(5564):2380-1. PubMed ID: 11923515 [No Abstract] [Full Text] [Related]
4. Development of subtype-selective oestrogen receptor-based therapeutics. Nilsson S; Koehler KF; Gustafsson JÅ Nat Rev Drug Discov; 2011 Sep; 10(10):778-92. PubMed ID: 21921919 [TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Lewis JS; Jordan VC Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919 [TBL] [Abstract][Full Text] [Related]
6. A reconsideration of tamoxifen use for breast cancer. Wang PH; Chao HT Taiwan J Obstet Gynecol; 2007 Jun; 46(2):93-5. PubMed ID: 17638615 [No Abstract] [Full Text] [Related]
7. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Shim JS; Li RJ; Lv J; Head SA; Yang EJ; Liu JO Cancer Lett; 2015 Jun; 362(1):106-15. PubMed ID: 25799952 [TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Jordan VC Nat Rev Cancer; 2007 Jan; 7(1):46-53. PubMed ID: 17186017 [TBL] [Abstract][Full Text] [Related]
9. [Selective estrogen receptor modulators]. Zasławski R; Surowiak P; Zabel M Pol Arch Med Wewn; 2004 Nov; 112(5):1393-8. PubMed ID: 15773525 [No Abstract] [Full Text] [Related]
10. The interplay between cholesterol and breast cancer: is there a potential role for statin therapy? Potluri R; Carter PR; Lavu D; Bainey KR Future Oncol; 2018 Aug; 14(19):1885-1888. PubMed ID: 30051723 [No Abstract] [Full Text] [Related]
11. Prevention of ER-negative breast cancer: where do we stand? Cazzaniga M; Bonanni B Eur J Cancer Prev; 2012 Mar; 21(2):171-81. PubMed ID: 21968686 [TBL] [Abstract][Full Text] [Related]
12. Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer. McCafferty MP; McNeill RE; Miller N; Kerin MJ Breast Cancer Res Treat; 2009 Aug; 116(3):425-32. PubMed ID: 19507020 [TBL] [Abstract][Full Text] [Related]
13. The selective estrogen receptor modulators in breast cancer prevention. Li F; Dou J; Wei L; Li S; Liu J Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504 [TBL] [Abstract][Full Text] [Related]
14. Estrogen and progesterone receptors in breast cancer. Ma CX Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867 [No Abstract] [Full Text] [Related]
15. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. Feldt M; Bjarnadottir O; Kimbung S; Jirström K; Bendahl PO; Veerla S; Grabau D; Hedenfalk I; Borgquist S J Transl Med; 2015 Apr; 13():133. PubMed ID: 25925673 [TBL] [Abstract][Full Text] [Related]
18. [Where do SERMs stand in the light of clinical application?]. Takeuchi Y Nihon Rinsho; 2007 Nov; 65 Suppl 9():306-10. PubMed ID: 18159712 [No Abstract] [Full Text] [Related]
20. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. McDonnell DP; Chang CY; Nelson ER Climacteric; 2014 Dec; 17 Suppl 2(0 2):60-5. PubMed ID: 25320023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]